A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer

Trial Profile

A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Taladegib (Primary)
  • Indications Advanced breast cancer; Basal cell cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly; Ignyta
  • Most Recent Events

    • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 19 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top